Cargando…
Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa
Dolutegravir 50 mg is registered for use in children weighing 20–40 kg. This approval is based on data from an African paediatric cohort, and no pharmacokinetic data was available from children outside of Africa. This study provides further evidence of the effective use of dolutegravir 50 mg in chil...
Autores principales: | Waalewijn, Hylke, Stol, Kim, van der Knaap, Linda, Fraaij, Pieter L.A., Vermont, Clementien, van Rossum, Annemarie M.C., Strik-Albers, Riet, Burger, David M., Svensson, Elin M., Colbers, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612713/ https://www.ncbi.nlm.nih.gov/pubmed/36111542 http://dx.doi.org/10.1097/QAD.0000000000003350 |
Ejemplares similares
-
Prevalence and Impact of Fatigue in Children with Primary Immunodeficiency Disorders: a Quantitative Single-Center Study
por: Visser, Eline, et al.
Publicado: (2022) -
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Waalewijn, Hylke, et al.
Publicado: (2022) -
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
por: Bollen, Pauline D J, et al.
Publicado: (2020) -
Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023) -
Continuous renal replacement therapy in neonates weighing less than 3 kg
por: Sohn, Young Bae, et al.
Publicado: (2012)